Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free RMD Stock Alerts

ResMed (RMD) Financials

ResMed logo
$192.41 -1.16 (-0.60%)
Closing price 03:59 PM Eastern
Extended Trading
$193.72 +1.31 (+0.68%)
As of 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ResMed

Annual Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 353 352 342 316 405 622 475 779 898 1,021 1,401
Consolidated Net Income / (Loss)		 353 352 342 316 405 622 475 779 898 1,021 1,401
Net Income / (Loss) Continuing Operations		 353 352 342 316 405 622 475 779 898 1,021 1,401
Total Pre-Tax Income 		436 440 419 521 519 733 884 960 1,102 1,265 1,678
Total Operating Income		 409 429 426 542 579 810 904 1,000 1,132 1,320 1,685
Total Gross Profit		 1,011 1,066 1,202 1,335 1,494 1,718 1,839 2,024 2,356 2,655 3,055
Total Revenue		 1,679 1,839 2,067 2,340 2,607 2,957 3,197 3,578 4,223 4,685 5,146
Total Cost of Revenue		 668 772 865 1,005 1,113 1,239 1,358 1,554 1,867 2,030 2,091
Operating Cost of Revenue		 668 772 865 1,005 1,113 1,239 1,358 1,554 1,867 2,030 2,091
Total Operating Expenses		 602 638 776 793 915 908 935 1,024 1,224 1,335 1,370
Selling, General & Admin Expense		 479 488 554 600 645 677 670 738 874 917 991
Research & Development Expense		 115 119 144 155 181 202 225 254 288 308 331
Amortization Expense		 8.67 24 47 19 32 30 31 31 42 47 45
Total Other Income / (Expense), net		 27 11 -7.06 -21 -60 -77 -20 -40 -30 -55 -7.80
Interest & Investment Income		 26 17 17 16 -14 -25 -11 -31 -55 -48 3.64
Other Income / (Expense), net		 6.25 4.96 4.10 -8.54 -11 -12 15 -9.01 24 -7.54 -16
Income Tax Expense		 83 87 76 206 114 111 409 181 204 244 277
Basic Earnings per Share		 $2.51 $2.51 $2.42 $2.21 $2.83 $4.31 $3.27 $5.34 $6.12 $6.94 $9.55
Weighted Average Basic Shares Outstanding		 140.47M 140.24M 141.36M 142.76M 143.11M 144.34M 145.31M 146.07M 146.77M 147.02M 146.72M
Diluted Earnings per Share		 $2.47 $2.49 $2.40 $2.19 $2.80 $4.27 $3.24 $5.30 $6.09 $6.92 $9.51
Weighted Average Diluted Shares Outstanding		 142.69M 141.67M 142.45M 143.99M 144.48M 145.65M 146.45M 147.04M 147.46M 147.55M 147.34M
Weighted Average Basic & Diluted Shares Outstanding		 140.60M 140.40M 141.40M 142.80M 143M 144.90M 145.68K 146.42M 147.07M 146.93M 146.41M
Cash Dividends to Common per Share		 $1.12 $1.20 $1.32 $1.40 $1.48 $1.56 $1.56 $1.68 $1.76 $1.92 $2.12

Quarterly Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 219 209 300 292 311 345 365 380 349 393 399
Consolidated Net Income / (Loss)		 219 209 300 292 311 345 365 380 349 393 399
Net Income / (Loss) Continuing Operations		 219 209 300 292 311 345 365 380 349 393 399
Total Pre-Tax Income 		272 259 375 358 383 418 418 458 447 496 502
Total Operating Income		 289 275 375 381 387 417 426 455 447 492 500
Total Gross Profit		 600 647 693 716 717 751 766 820 821 879 891
Total Revenue		 1,102 1,163 1,197 1,223 1,225 1,282 1,292 1,348 1,336 1,423 1,431
Operating Revenue		 1,102 1,163 1,197 1,223 - - - - 1,336 1,423 1,431
Total Cost of Revenue		 502 516 504 508 507 531 525 528 515 544 540
Operating Cost of Revenue		 502 516 504 508 507 531 525 528 515 544 540
Total Operating Expenses		 311 372 318 334 330 334 340 366 374 387 391
Selling, General & Admin Expense		 223 222 230 242 239 242 245 265 259 278 286
Research & Development Expense		 76 74 77 81 80 81 84 86 87 91 94
Amortization Expense		 12 12 11 11 11 11 11 12 12 12 11
Other Operating Expenses / (Income)		 - - - - - - - - 0.00 0.00 0.00
Restructuring Charge		 - 64 0.00 - - - 0.00 - 16 5.94 0.00
Total Other Income / (Expense), net		 -17 -16 0.84 -23 -3.82 1.08 -8.58 3.51 0.26 4.49 2.50
Interest & Investment Income		 -19 -13 -11 -45 0.96 1.08 0.34 1.27 10 9.46 14
Other Income / (Expense), net		 2.05 -2.57 11 -18 -3.12 0.78 -9.70 -3.51 -10 -4.98 -12
Income Tax Expense		 53 51 75 65 72 74 53 78 98 104 104
Basic Earnings per Share		 $1.49 $1.42 $2.04 $1.99 $2.12 $2.35 $2.49 $2.59 $2.38 $2.69 $2.74
Weighted Average Basic Shares Outstanding		 147.08M 147.13M 146.96M 147.02M 146.86M 146.81M 146.72M 146.72M 146.18M 145.84M 145.34M
Diluted Earnings per Share		 $1.49 $1.42 $2.04 $1.97 $2.11 $2.34 $2.48 $2.58 $2.37 $2.68 $2.74
Weighted Average Diluted Shares Outstanding		 147.49M 147.55M 147.45M 147.55M 147.60M 147.48M 147.22M 147.34M 146.90M 146.37M 145.72M
Weighted Average Basic & Diluted Shares Outstanding		 147.09M 147.09M 146.91M 146.93M 146.80M 146.87M 146.63M 146.41M 145.97M 145.68M 145.06M
Cash Dividends to Common per Share		 $0.48 $0.48 $0.48 $0.48 $0.53 $0.53 $0.53 $0.53 $0.60 $0.60 $0.60

Annual Cash Flow Statements for ResMed

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 -163 14 91 -633 -42 316 -168 -22 -46 10 971
Net Cash From Operating Activities		 409 548 414 505 459 802 737 351 693 1,401 1,752
Net Cash From Continuing Operating Activities		 409 548 414 505 459 802 737 351 693 1,401 1,752
Net Income / (Loss) Continuing Operations		 353 352 342 316 405 622 475 779 898 1,021 1,401
Consolidated Net Income / (Loss)		 353 352 342 316 405 622 475 779 898 1,021 1,401
Depreciation Expense		 73 87 112 120 151 155 157 160 165 177 198
Amortization Expense		 - - - 0.00 0.00 27 35 34 32 39 37
Non-Cash Adjustments To Reconcile Net Income		 48 50 39 60 81 97 69 86 60 119 98
Changes in Operating Assets and Liabilities, net		 -65 59 -80 9.47 -177 -98 1.41 -708 -462 45 17
Net Cash From Investing Activities		 -143 -1,126 -82 -102 -1,076 -180 -158 -230 -1,160 -270 -200
Net Cash From Continuing Investing Activities		 -143 -1,126 -82 -102 -1,076 -180 -158 -230 -1,160 -270 -200
Purchase of Property, Plant & Equipment		 -63 -59 -62 -63 -69 -95 -103 -135 -120 -99 -90
Acquisitions		 -39 -1,051 -17 -9.78 -960 -39 -53 -64 -1,027 -149 -150
Purchase of Investments		 -42 -8.97 -6.46 -29 -47 -32 -22 -21 -32 -13 -6.42
Sale and/or Maturity of Investments		 - -7.10 3.32 - - -14 19 -10 19 -8.70 46
Net Cash From Financing Activities		 -256 613 -263 -1,027 581 -317 -765 -128 423 -1,119 -606
Net Cash From Continuing Financing Activities		 -256 613 -263 -1,027 581 -317 -765 -128 423 -1,119 -606
Repayment of Debt		 -182 -284 -545 -1,146 -712 -1,284 -612 -166 -405 -835 -40
Repurchase of Common Equity		 -160 -102 - -54 -23 - - 0.00 0.00 -150 -300
Payment of Dividends		 -158 -169 -198 -200 -213 -225 -230 -245 -261 -284 -312
Issuance of Debt		 180 1,140 450 350 1,519 1,190 90 288 1,070 105 0.00
Issuance of Common Equity		 39 28 38 39 37 48 38 47 49 53 74
Other Financing Activities, net		 25 - -8.16 -15 -28 -46 -50 -52 -31 -8.76 -29
Effect of Exchange Rate Changes		 -173 -21 21 -9.74 -5.56 11 18 -14 -2.15 -1.72 26
Cash Interest Paid		 - 11 28 28 36 40 24 22 47 46 28
Cash Income Taxes Paid		 49 69 93 171 243 180 221 478 217 278 214

Quarterly Cash Flow Statements for ResMed

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -19 1.15 28 0.45 188 96 411 277 174 33 243
Net Cash From Operating Activities		 286 273 402 440 326 309 579 539 457 340 554
Net Cash From Continuing Operating Activities		 286 273 402 440 326 309 579 539 457 340 554
Net Income / (Loss) Continuing Operations		 219 209 300 292 311 345 365 380 349 393 399
Consolidated Net Income / (Loss)		 219 209 300 292 311 345 365 380 349 393 399
Depreciation Expense		 45 45 43 44 45 46 44 64 48 50 59
Amortization Expense		 8.51 8.59 11 11 8.98 9.46 8.24 11 9.97 12 10
Non-Cash Adjustments To Reconcile Net Income		 23 54 6.08 36 20 23 29 26 26 27 35
Changes in Operating Assets and Liabilities, net		 -9.59 -44 41 57 -59 -115 132 59 25 -142 51
Net Cash From Investing Activities		 -149 -41 -33 -47 2.15 -37 -32 -134 -53 -51 -58
Net Cash From Continuing Investing Activities		 -149 -41 -33 -47 2.15 -37 -32 -134 -53 -51 -58
Purchase of Property, Plant & Equipment		 -30 -23 -21 -25 -18 -21 -21 -31 -43 -29 -34
Acquisitions		 -114 -8.71 -5.00 -21 -1.77 -3.50 -2.99 -142 -3.34 -6.54 -30
Purchase of Investments		 -3.68 -3.63 -2.39 -3.07 -1.35 -20 -2.05 -2.01 -2.17 -4.23 -20
Sale and/or Maturity of Investments		 -1.25 -5.46 -4.58 2.58 23 7.42 -5.95 41 -4.10 -12 27
Net Cash From Financing Activities		 -151 -239 -336 -393 -151 -148 -144 -164 -230 -258 -255
Net Cash From Continuing Financing Activities		 -151 -239 -336 -393 -151 -148 -144 -164 -230 -258 -255
Repurchase of Common Equity		 0.00 -50 -50 -50 -50 -75 -75 -100 -150 -175 -175
Payment of Dividends		 -72 -71 -70 -72 -79 -78 -78 -78 -88 -88 -87
Issuance of Common Equity		 0.98 20 4.89 28 8.38 27 9.02 30 8.21 30 7.43
Other Financing Activities, net		 -0.23 -7.80 -0.31 0.87 -0.39 -17 -0.36 -11 -0.72 -20 -0.42
Effect of Exchange Rate Changes		 -4.96 8.42 -5.30 0.13 11 -29 7.96 36 -0.07 2.77 2.58
Cash Interest Paid		 15 14 11 5.92 7.35 -0.07 14 6.91 6.85 6.61 6.53
Cash Income Taxes Paid		 77 97 62 43 106 119 -27 16 62 148 72

Annual Balance Sheets for ResMed

This table presents ResMed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 2,182 3,257 3,468 3,064 4,108 4,587 4,728 5,096 6,752 6,872 8,174
Total Current Assets		 1,408 1,420 1,644 1,066 1,145 1,523 1,575 1,931 2,368 2,358 3,506
Cash & Equivalents		 717 731 822 189 147 463 295 274 228 238 1,209
Accounts Receivable		 363 382 451 484 528 475 614 576 705 837 939
Inventories, net		 247 224 268 269 350 417 457 744 998 822 928
Prepaid Expenses		 81 82 103 125 120 75 208 338 437 460 429
Plant, Property, & Equipment, net		 388 384 394 387 387 417 463 498 538 548 551
Total Noncurrent Assets		 386 1,453 1,430 1,612 2,575 2,647 2,690 2,666 3,846 3,967 4,118
Goodwill		 264 1,059 1,065 1,069 1,856 1,890 1,928 1,936 2,770 2,842 3,047
Intangible Assets		 47 300 262 215 522 448 393 346 552 486 465
Noncurrent Deferred & Refundable Income Taxes		 46 55 62 54 45 41 80 80 133 204 253
Other Noncurrent Operating Assets		 28 38 42 274 151 267 289 304 390 435 353
Total Liabilities & Shareholders' Equity		 2,182 3,257 3,468 3,064 4,108 4,587 4,728 5,096 6,752 6,872 8,174
Total Liabilities		 594 1,562 1,508 1,005 2,035 2,090 1,842 1,735 2,622 2,008 2,207
Total Current Liabilities		 266 638 360 511 556 603 912 689 759 911 1,019
Short-Term Debt		 - 299 - 11 12 12 12 9.92 9.90 9.90 9.90
Accounts Payable		 81 93 93 93 116 136 138 159 151 238 278
Accrued Expenses		 133 157 186 186 266 270 321 345 366 378 402
Current Deferred Revenue		 36 50 52 61 89 99 110 109 138 153 166
Current Deferred & Payable Income Tax Liabilities		 16 39 29 160 73 65 308 45 72 108 132
Other Current Liabilities		 - - - - 0.00 21 24 22 22 25 31
Total Noncurrent Liabilities		 328 924 1,148 494 1,479 1,488 931 1,046 1,863 1,098 1,187
Long-Term Debt		 301 873 1,079 270 1,259 1,164 643 765 1,431 697 658
Noncurrent Deferred Revenue		 21 40 53 210 207 200 154 144 156 137 157
Noncurrent Deferred & Payable Income Tax Liabilities		 6.37 9.06 14 13 11 13 11 9.71 91 79 78
Other Noncurrent Operating Liabilities		 0.00 1.21 2.43 0.92 2.06 110 122 126 185 184 295
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968
Total Preferred & Common Equity		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968
Common Stock		 1,229 1,304 1,380 1,451 1,512 1,571 1,623 1,683 1,773 1,897 2,034
Retained Earnings		 1,976 2,160 2,316 2,432 2,436 2,833 3,080 3,614 4,253 4,992 6,081
Treasury Stock		 -1,445 -1,547 -1,547 -1,600 -1,623 -1,623 -1,623 -1,623 -1,623 -1,773 -2,073
Accumulated Other Comprehensive Income / (Loss)		 -174 -223 -189 -224 -253 -284 -193 -313 -273 -252 -75

Quarterly Balance Sheets for ResMed

This table presents ResMed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 6,752 6,741 6,905 6,815 6,872 7,222 7,141 7,567 8,308 8,503 8,784
Total Current Assets		 2,368 2,305 2,378 2,351 2,358 2,641 2,836 3,208 3,626 3,819 4,064
Cash & Equivalents		 228 209 210 238 238 426 522 933 1,384 1,417 1,661
Accounts Receivable		 705 692 730 779 837 811 860 908 907 986 999
Inventories, net		 998 958 933 829 822 918 882 863 946 922 912
Prepaid Expenses		 437 445 505 505 460 486 572 505 389 494 493
Plant, Property, & Equipment, net		 538 534 552 540 548 560 520 535 564 564 567
Total Noncurrent Assets		 3,846 3,902 3,975 3,924 3,967 4,021 3,785 3,823 4,119 4,120 4,153
Goodwill		 2,770 2,812 2,862 2,836 2,842 2,886 2,805 2,849 3,044 3,044 3,043
Intangible Assets		 552 563 528 501 486 479 438 430 447 430 425
Noncurrent Deferred & Refundable Income Taxes		 133 138 156 162 204 221 209 217 276 286 313
Other Noncurrent Operating Assets		 390 389 429 424 435 436 332 327 352 360 372
Total Liabilities & Shareholders' Equity		 6,752 6,741 6,905 6,815 6,872 7,222 7,141 7,567 8,308 8,503 8,784
Total Liabilities		 2,622 2,490 2,423 2,185 2,008 2,027 1,888 2,021 2,187 2,182 2,292
Total Current Liabilities		 759 771 764 773 911 904 852 941 1,256 1,248 1,351
Short-Term Debt		 9.90 9.91 9.90 9.90 9.90 9.90 9.91 9.91 260 260 260
Accounts Payable		 151 177 202 177 238 249 220 223 267 250 273
Accrued Expenses		 366 348 332 356 378 366 353 386 396 392 446
Current Deferred Revenue		 138 147 149 151 153 157 157 160 168 176 179
Current Deferred & Payable Income Tax Liabilities		 72 67 47 55 108 94 85 133 135 140 163
Other Current Liabilities		 22 22 24 24 25 28 28 29 30 30 29
Total Noncurrent Liabilities		 1,863 1,720 1,659 1,412 1,098 1,123 1,036 1,080 932 934 941
Long-Term Debt		 1,431 1,352 1,217 997 697 668 663 663 409 404 404
Noncurrent Deferred Revenue		 156 134 140 144 137 144 147 151 159 160 163
Noncurrent Deferred & Payable Income Tax Liabilities		 91 88 89 87 79 84 77 79 78 78 78
Other Noncurrent Operating Liabilities		 185 147 214 184 184 228 150 187 286 293 296
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546 6,121 6,321 6,492
Total Preferred & Common Equity		 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546 6,121 6,321 6,492
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546 6,121 6,321 6,492
Common Stock		 1,773 1,792 1,824 1,849 1,897 1,925 1,958 1,991 2,063 2,104 2,135
Retained Earnings		 4,253 4,402 4,540 4,770 4,992 5,225 5,492 5,779 6,342 6,647 6,959
Treasury Stock		 -1,623 -1,623 -1,673 -1,723 -1,773 -1,823 -1,898 -1,973 -2,223 -2,400 -2,577
Accumulated Other Comprehensive Income / (Loss)		 -273 -320 -208 -265 -252 -132 -299 -251 -61 -30 -25

Annual Metrics And Ratios for ResMed

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 7.97% 9.52% 12.40% 13.23% 11.38% 13.44% 8.11% 11.93% 18.02% 10.95% 9.84%
EBITDA Growth		 1.90% 6.59% 4.09% 20.51% 10.12% 36.08% 13.40% 6.77% 14.24% 12.90% 24.67%
EBIT Growth		 2.34% 4.43% -0.93% 24.05% 6.61% 40.27% 15.17% 7.92% 16.65% 13.50% 27.24%
NOPAT Growth		 2.11% 3.81% 1.21% -5.76% 37.71% 52.00% -29.33% 67.28% 13.60% 15.53% 32.08%
Net Income Growth		 2.20% -0.14% -2.87% -7.80% 28.20% 53.65% -23.67% 64.26% 15.15% 13.75% 37.20%
EPS Growth		 3.35% 0.81% -3.61% -8.75% 27.85% 52.50% -24.12% 63.58% 14.91% 13.63% 37.43%
Operating Cash Flow Growth		 0.31% 34.02% -24.43% 21.97% -9.10% 74.76% -8.17% -52.34% 97.44% 102.11% 25.00%
Free Cash Flow Firm Growth		 52.10% -298.00% 143.00% 47.12% -250.67% 213.51% -33.16% -56.57% -386.21% 292.53% 22.10%
Invested Capital Growth		 1.50% 82.48% 3.78% -2.94% 48.53% 0.44% 1.11% 19.00% 38.34% -0.19% 1.76%
Revenue Q/Q Growth		 2.31% 3.70% 1.88% 2.94% 3.22% 2.26% 3.42% 1.09% 5.16% 2.21% 2.49%
EBITDA Q/Q Growth		 -0.68% 6.03% 1.17% 3.54% -2.48% 15.99% 1.74% -0.02% 4.47% 4.68% 5.99%
EBIT Q/Q Growth		 -0.30% 4.92% 1.21% 3.65% -4.89% 16.43% 2.09% 0.04% 4.31% 5.53% 5.58%
NOPAT Q/Q Growth		 0.76% 0.25% 6.84% 2.56% -5.51% 16.76% 2.68% 1.51% 2.15% 8.42% 4.84%
Net Income Q/Q Growth		 -0.08% -1.22% 5.71% 2.67% -9.20% 21.27% 3.78% -0.01% 4.01% 6.53% 6.66%
EPS Q/Q Growth		 0.41% -0.80% 4.80% 2.82% -9.09% 20.96% 3.51% -0.19% 3.92% 6.46% 6.85%
Operating Cash Flow Q/Q Growth		 -3.90% 8.43% -1.48% -2.11% 2.78% 30.70% -12.34% -29.51% 29.50% 16.91% 5.97%
Free Cash Flow Firm Q/Q Growth		 -9.37% -848.63% 155.72% 14.60% -5.84% 29.79% -17.27% -22.41% 11.31% 23.04% -9.71%
Invested Capital Q/Q Growth		 3.55% 53.62% 0.95% -0.96% -0.45% -2.15% 1.13% 2.78% 1.00% -1.22% 2.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 60.24% 58.00% 58.15% 57.04% 57.32% 58.09% 57.53% 56.57% 55.78% 56.67% 59.36%
EBITDA Margin		 29.10% 28.32% 26.23% 27.91% 27.60% 33.10% 34.72% 33.12% 32.06% 32.62% 37.03%
Operating Margin		 24.38% 23.33% 20.60% 23.15% 22.22% 27.38% 28.27% 27.96% 26.80% 28.17% 32.75%
EBIT Margin		 24.75% 23.60% 20.80% 22.79% 21.81% 26.97% 28.73% 27.70% 27.38% 28.01% 32.45%
Profit (Net Income) Margin		 21.02% 19.17% 16.56% 13.49% 15.52% 21.02% 14.84% 21.78% 21.25% 21.79% 27.22%
Tax Burden Percent		 80.95% 80.17% 81.74% 60.54% 77.98% 84.80% 53.70% 81.15% 81.47% 80.72% 83.50%
Interest Burden Percent		 104.92% 101.30% 97.41% 97.75% 91.26% 91.92% 96.21% 96.89% 95.27% 96.38% 100.46%
Effective Tax Rate		 19.05% 19.83% 18.26% 39.46% 22.02% 15.20% 46.30% 18.85% 18.53% 19.28% 16.50%
Return on Invested Capital (ROIC)		 28.51% 20.80% 15.99% 15.02% 16.89% 21.44% 15.03% 22.84% 20.04% 19.96% 26.16%
ROIC Less NNEP Spread (ROIC-NNEP)		 24.28% 89.76% 14.34% 7.91% 9.15% 14.37% 13.03% 15.34% 17.16% 14.67% 44.17%
Return on Net Nonoperating Assets (RNNOA)		 -7.41% 0.67% 2.74% 0.69% 2.69% 5.77% 2.60% 2.12% 3.93% 2.74% -0.29%
Return on Equity (ROE)		 21.10% 21.47% 18.73% 15.70% 19.59% 27.21% 17.63% 24.96% 23.96% 22.70% 25.86%
Cash Return on Invested Capital (CROIC)		 27.02% -37.60% 12.28% 18.00% -22.16% 21.00% 13.93% 5.49% -12.14% 20.15% 24.41%
Operating Return on Assets (OROA)		 18.29% 15.96% 12.78% 16.33% 15.86% 18.34% 19.72% 20.18% 19.52% 19.27% 22.19%
Return on Assets (ROA)		 15.54% 12.96% 10.18% 9.66% 11.28% 14.30% 10.19% 15.87% 15.15% 14.99% 18.62%
Return on Common Equity (ROCE)		 21.10% 21.47% 18.73% 15.70% 19.59% 27.21% 17.63% 24.96% 23.96% 22.70% 25.86%
Return on Equity Simple (ROE_SIMPLE)		 22.23% 20.79% 17.46% 15.33% 19.52% 24.90% 16.44% 23.19% 21.73% 20.99% 0.00%
Net Operating Profit after Tax (NOPAT)		 331 344 348 328 452 687 485 812 922 1,065 1,407
NOPAT Margin		 19.73% 18.70% 16.84% 14.02% 17.33% 23.22% 15.18% 22.69% 21.84% 22.74% 27.34%
Net Nonoperating Expense Percent (NNEP)		 4.23% -68.96% 1.65% 7.11% 7.75% 7.07% 2.00% 7.50% 2.87% 5.29% -18.01%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - - 21.21%
Cost of Revenue to Revenue		 39.76% 42.00% 41.85% 42.96% 42.68% 41.91% 42.47% 43.43% 44.22% 43.33% 40.64%
SG&A Expenses to Revenue		 28.51% 26.54% 26.80% 25.65% 24.75% 22.88% 20.97% 20.61% 20.70% 19.57% 19.26%
R&D to Revenue		 6.84% 6.45% 6.99% 6.63% 6.93% 6.83% 7.05% 7.09% 6.81% 6.56% 6.44%
Operating Expenses to Revenue		 35.87% 34.67% 37.54% 33.89% 35.10% 30.71% 29.26% 28.62% 28.98% 28.50% 26.61%
Earnings before Interest and Taxes (EBIT)		 415 434 430 533 569 798 918 991 1,156 1,312 1,670
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 489 521 542 653 719 979 1,110 1,185 1,354 1,529 1,906
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.45 4.76 5.22 6.76 8.07 10.73 12.09 8.94 7.67 5.77 6.34
Price to Tangible Book Value (P/TBV)		 5.54 24.01 16.15 17.97 0.00 169.08 61.73 27.85 39.26 18.26 15.40
Price to Revenue (P/Rev)		 4.21 4.39 4.95 5.95 6.41 9.06 10.91 8.39 7.50 5.99 7.35
Price to Earnings (P/E)		 20.02 22.88 29.90 44.12 41.31 43.12 73.53 38.54 35.31 27.48 27.01
Dividend Yield		 2.23% 2.09% 2.25% 1.44% 1.27% 0.84% 0.65% 0.82% 0.82% 1.01% 0.82%
Earnings Yield		 5.00% 4.37% 3.34% 2.27% 2.42% 2.32% 1.36% 2.60% 2.83% 3.64% 3.70%
Enterprise Value to Invested Capital (EV/IC)		 5.68 3.98 4.73 6.51 5.58 8.57 10.86 7.91 6.16 5.35 6.87
Enterprise Value to Revenue (EV/Rev)		 3.96 4.63 5.08 5.99 6.84 9.31 11.03 8.53 7.79 6.09 7.25
Enterprise Value to EBITDA (EV/EBITDA)		 13.61 16.33 19.35 21.46 24.80 28.11 31.76 25.77 24.30 18.66 19.57
Enterprise Value to EBIT (EV/EBIT)		 16.00 19.60 24.40 26.29 31.38 34.51 38.38 30.81 28.46 21.73 22.33
Enterprise Value to NOPAT (EV/NOPAT)		 20.07 24.73 30.14 42.74 39.49 40.08 72.65 37.62 35.68 26.77 26.50
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.26 15.52 25.33 27.76 38.86 34.30 47.85 86.97 47.46 20.36 21.29
Enterprise Value to Free Cash Flow (EV/FCFF)		 21.17 0.00 39.25 35.65 0.00 40.92 78.43 156.44 0.00 26.52 28.39
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.19 0.69 0.55 0.14 0.61 0.47 0.23 0.23 0.35 0.15 0.11
Long-Term Debt to Equity		 0.19 0.52 0.55 0.13 0.61 0.47 0.22 0.23 0.35 0.14 0.11
Financial Leverage		 -0.31 0.01 0.19 0.09 0.29 0.40 0.20 0.14 0.23 0.19 -0.01
Leverage Ratio		 1.36 1.66 1.84 1.63 1.74 1.90 1.73 1.57 1.58 1.51 1.39
Compound Leverage Factor		 1.42 1.68 1.79 1.59 1.58 1.75 1.67 1.52 1.51 1.46 1.40
Debt to Total Capital		 15.92% 40.90% 35.49% 12.03% 38.01% 32.02% 18.51% 18.74% 25.87% 12.69% 10.07%
Short-Term Debt to Total Capital		 0.00% 10.44% 0.00% 0.49% 0.36% 0.33% 0.34% 0.24% 0.18% 0.18% 0.15%
Long-Term Debt to Total Capital		 15.92% 30.46% 35.49% 11.54% 37.66% 31.69% 18.17% 18.50% 25.69% 12.52% 9.92%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 84.08% 59.10% 64.51% 87.97% 61.99% 67.98% 81.49% 81.26% 74.13% 87.31% 89.93%
Debt to EBITDA		 0.62 2.25 1.99 0.43 1.77 1.20 0.59 0.65 1.06 0.46 0.35
Net Debt to EBITDA		 -0.85 0.85 0.47 0.14 1.56 0.73 0.32 0.42 0.90 0.31 -0.28
Long-Term Debt to EBITDA		 0.62 1.68 1.99 0.41 1.75 1.19 0.58 0.65 1.06 0.46 0.35
Debt to NOPAT		 0.91 3.41 3.10 0.86 2.81 1.71 1.35 0.96 1.56 0.66 0.47
Net Debt to NOPAT		 -1.26 1.28 0.74 0.28 2.49 1.04 0.74 0.62 1.32 0.44 -0.38
Long-Term Debt to NOPAT		 0.91 2.54 3.10 0.82 2.79 1.70 1.33 0.94 1.55 0.65 0.47
Altman Z-Score		 10.42 5.32 6.45 10.98 7.02 10.02 13.76 13.02 9.61 10.96 13.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.28 2.23 4.57 2.08 2.06 2.53 1.73 2.80 3.12 2.59 3.44
Quick Ratio		 4.05 1.75 3.53 1.32 1.22 1.56 1.00 1.23 1.23 1.18 2.11
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 314 -622 267 393 -592 673 449 195 -559 1,076 1,313
Operating Cash Flow to CapEx		 654.14% 936.09% 665.48% 807.00% 668.10% 841.56% 717.27% 260.43% 579.33% 1,408.87% 1,949.13%
Free Cash Flow to Firm to Interest Expense		 54.33 -55.47 9.47 13.87 -16.39 17.09 19.02 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 70.76 48.90 14.66 17.81 12.70 20.38 31.18 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 59.94 43.67 12.46 15.60 10.80 17.96 26.83 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.74 0.68 0.61 0.72 0.73 0.68 0.69 0.73 0.71 0.69 0.68
Accounts Receivable Turnover		 4.65 4.94 4.96 5.01 5.15 5.90 5.87 6.01 6.59 6.08 5.79
Inventory Turnover		 3.24 3.28 3.51 3.74 3.60 3.23 3.11 2.59 2.14 2.23 2.39
Fixed Asset Turnover		 4.08 4.76 5.31 5.99 6.74 7.35 7.26 7.44 8.15 8.63 9.37
Accounts Payable Turnover		 8.02 8.89 9.33 10.84 10.67 9.85 9.92 10.45 12.05 10.45 8.11
Days Sales Outstanding (DSO)		 78.50 73.91 73.52 72.85 70.87 61.91 62.17 60.71 55.35 60.07 63.01
Days Inventory Outstanding (DIO)		 112.72 111.39 103.97 97.49 101.44 112.89 117.47 141.05 170.24 163.64 152.71
Days Payable Outstanding (DPO)		 45.53 41.05 39.10 33.67 34.19 37.04 36.80 34.91 30.30 34.93 45.02
Cash Conversion Cycle (CCC)		 145.69 144.25 138.39 136.67 138.11 137.76 142.84 166.85 195.30 188.79 170.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,171 2,136 2,217 2,152 3,196 3,210 3,246 3,862 5,343 5,333 5,427
Invested Capital Turnover		 1.44 1.11 0.95 1.07 0.97 0.92 0.99 1.01 0.92 0.88 0.96
Increase / (Decrease) in Invested Capital		 17 966 81 -65 1,044 14 36 617 1,481 -10 94
Enterprise Value (EV)		 6,647 8,505 10,490 14,018 17,839 27,518 35,252 30,537 32,904 28,523 37,289
Market Capitalization		 7,064 8,063 10,233 13,925 16,715 26,805 34,892 30,036 31,691 28,054 37,830
Book Value per Share		 $11.26 $12.07 $13.82 $14.42 $14.45 $17.26 $19.83 $22.97 $28.11 $33.11 $40.70
Tangible Book Value per Share		 $9.05 $2.39 $4.47 $5.43 ($2.14) $1.10 $3.88 $7.37 $5.49 $10.46 $16.75
Total Capital		 1,888 2,868 3,039 2,340 3,343 3,673 3,541 4,136 5,571 5,571 6,636
Total Debt		 301 1,173 1,079 281 1,271 1,176 655 775 1,441 707 668
Total Long-Term Debt		 301 873 1,079 270 1,259 1,164 643 765 1,431 697 658
Net Debt		 -417 441 257 93 1,124 713 360 502 1,213 469 -541
Capital Expenditures (CapEx)		 63 59 62 63 69 95 103 135 120 99 90
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 424 350 462 377 454 470 380 978 1,391 1,219 1,287
Debt-free Net Working Capital (DFNWC)		 1,141 1,081 1,284 566 601 933 675 1,252 1,619 1,457 2,496
Net Working Capital (NWC)		 1,141 782 1,284 554 589 921 663 1,242 1,609 1,447 2,486
Net Nonoperating Expense (NNE)		 -22 -8.51 5.77 12 47 65 11 32 25 44 6.51
Net Nonoperating Obligations (NNO)		 -417 441 257 93 1,124 713 360 502 1,213 469 -541
Total Depreciation and Amortization (D&A)		 73 87 112 120 151 181 192 194 198 216 236
Debt-free, Cash-free Net Working Capital to Revenue		 25.26% 19.02% 22.35% 16.12% 17.43% 15.88% 11.88% 27.34% 32.95% 26.01% 25.01%
Debt-free Net Working Capital to Revenue		 67.98% 58.80% 62.12% 24.18% 23.07% 31.54% 21.11% 34.99% 38.34% 31.10% 48.51%
Net Working Capital to Revenue		 67.98% 42.52% 62.12% 23.69% 22.61% 31.14% 20.74% 34.72% 38.11% 30.89% 48.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.51 $2.51 $2.42 $2.21 $2.83 $4.31 $3.27 $5.34 $6.12 $6.94 $9.55
Adjusted Weighted Average Basic Shares Outstanding		 140.47M 140.24M 141.36M 142.76M 143.11M 144.34M 145.31M 146.07M 146.77M 147.02M 146.72M
Adjusted Diluted Earnings per Share		 $2.47 $2.49 $2.40 $2.19 $2.80 $4.27 $3.24 $5.30 $6.09 $6.92 $9.51
Adjusted Weighted Average Diluted Shares Outstanding		 142.69M 141.67M 142.45M 143.99M 144.48M 145.65M 146.45M 147.04M 147.46M 147.55M 147.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 140.52M 140.70M 142.21M 142.68M 143.67M 144.90M 145.68K 146.42M 147.07M 146.93M 146.41M
Normalized Net Operating Profit after Tax (NOPAT)		 331 349 373 339 491 686 490 813 939 1,117 1,407
Normalized NOPAT Margin		 19.73% 19.00% 18.06% 14.49% 18.84% 23.20% 15.32% 22.73% 22.23% 23.85% 27.34%
Pre Tax Income Margin		 25.96% 23.91% 20.26% 22.28% 19.91% 24.79% 27.64% 26.84% 26.09% 27.00% 32.60%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 71.91 38.72 15.23 18.81 15.72 20.26 38.87 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 57.34 30.69 12.33 11.57 12.49 17.45 20.54 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 61.09 33.50 13.02 16.60 13.82 17.84 34.53 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 46.52 25.47 10.12 9.36 10.59 15.02 16.19 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 44.69% 48.06% 57.85% 63.37% 52.55% 36.26% 48.52% 31.48% 29.04% 27.78% 22.26%
Augmented Payout Ratio		 90.12% 77.02% 57.85% 80.42% 58.20% 36.26% 48.52% 31.48% 29.04% 42.47% 43.67%

Quarterly Metrics And Ratios for ResMed

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 145,678,401.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 145,678,401.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 2.74
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 16.00% 12.48% 7.17% 9.01% 11.08% 10.26% 7.92% 10.20% 9.07% 10.98% 10.81%
EBITDA Growth		 9.36% -1.96% 23.32% 19.58% 27.12% 45.42% 6.32% 25.81% 12.85% 15.84% 18.97%
EBIT Growth		 7.41% -5.00% 26.76% 23.41% 32.01% 53.39% 7.92% 24.32% 13.62% 16.43% 17.22%
NOPAT Growth		 5.09% -3.85% 24.11% 36.36% 34.98% 55.26% 24.25% 20.99% 10.78% 13.18% 6.50%
Net Income Growth		 4.25% -7.16% 29.24% 27.25% 41.90% 65.05% 21.48% 29.93% 11.94% 13.92% 9.23%
EPS Growth		 4.20% -7.19% 29.11% 27.10% 41.61% 64.79% 21.57% 30.96% 12.32% 14.53% 10.48%
Operating Cash Flow Growth		 541.00% 112.10% 42.28% 85.36% 13.71% 13.12% 43.93% 22.42% 40.48% 10.08% -4.24%
Free Cash Flow Firm Growth		 -371.13% 100.61% 114.82% 125.68% 123.59% 4,977.63% 153.50% -12.03% 43.35% -48.60% -61.30%
Invested Capital Growth		 34.36% 4.03% 2.05% -0.19% 0.80% -1.72% -2.08% 1.76% -0.74% 3.03% 3.95%
Revenue Q/Q Growth		 -1.76% 5.49% 2.94% 2.19% 0.11% 4.70% 0.75% 4.36% -0.92% 6.53% 0.60%
EBITDA Q/Q Growth		 -1.34% -5.40% 35.21% -5.24% 4.88% 8.22% -1.15% 12.13% -5.93% 11.10% 1.52%
EBIT Q/Q Growth		 -1.00% -6.36% 41.64% -6.02% 5.90% 8.80% -0.35% 8.27% -3.22% 11.49% 0.33%
NOPAT Q/Q Growth		 2.01% -4.97% 35.43% 3.87% 0.97% 9.31% 8.38% 1.14% -7.55% 11.69% 1.98%
Net Income Q/Q Growth		 -4.46% -4.84% 43.91% -2.75% 6.54% 10.68% 5.93% 4.02% -8.21% 12.64% 1.56%
EPS Q/Q Growth		 -3.87% -4.70% 43.66% -3.43% 7.11% 10.90% 5.98% 4.03% -8.14% 13.08% 2.24%
Operating Cash Flow Q/Q Growth		 20.57% -4.70% 47.35% 9.47% -26.03% -5.20% 87.50% -6.89% -15.12% -25.71% 63.10%
Free Cash Flow Firm Q/Q Growth		 8.29% 100.75% 2,117.28% 68.12% -15.75% 61.69% 10.70% -41.66% 37.29% -42.02% -16.66%
Invested Capital Q/Q Growth		 1.11% 1.77% -1.81% -1.22% 2.12% -0.78% -2.17% 2.65% -0.38% 2.99% -1.30%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 54.44% 55.64% 57.88% 58.50% 58.57% 58.60% 59.33% 60.84% 61.46% 61.76% 62.25%
EBITDA Margin		 31.25% 28.03% 36.81% 34.14% 35.76% 36.96% 36.27% 38.97% 37.00% 38.59% 38.94%
Operating Margin		 26.22% 23.66% 31.29% 31.17% 31.63% 32.54% 33.00% 33.72% 33.43% 34.56% 34.92%
EBIT Margin		 26.40% 23.44% 32.25% 29.66% 31.38% 32.60% 32.25% 33.46% 32.68% 34.21% 34.11%
Profit (Net Income) Margin		 19.91% 17.96% 25.10% 23.89% 25.43% 26.88% 28.26% 28.17% 26.10% 27.59% 27.86%
Tax Burden Percent		 80.61% 80.48% 80.04% 81.69% 81.19% 82.38% 87.39% 82.90% 78.01% 79.13% 79.38%
Interest Burden Percent		 93.52% 95.21% 97.26% 98.61% 99.82% 100.07% 100.27% 101.56% 102.36% 101.94% 102.87%
Effective Tax Rate		 19.39% 19.52% 19.96% 18.31% 18.81% 17.62% 12.61% 17.10% 21.99% 20.87% 20.62%
Return on Invested Capital (ROIC)		 19.62% 15.90% 21.48% 22.35% 22.76% 24.23% 27.11% 26.74% 25.27% 26.91% 28.47%
ROIC Less NNEP Spread (ROIC-NNEP)		 18.07% 14.92% 21.55% 20.07% 22.32% 24.38% 24.16% 18.68% 25.18% 25.73% 28.16%
Return on Net Nonoperating Assets (RNNOA)		 4.09% 4.65% 5.35% 3.75% 3.32% 2.92% 1.21% -0.12% -1.03% -1.34% -2.94%
Return on Equity (ROE)		 23.72% 20.56% 26.84% 26.10% 26.08% 27.16% 28.32% 26.61% 24.24% 25.57% 25.53%
Cash Return on Invested Capital (CROIC)		 -9.51% 13.20% 16.36% 20.15% 20.34% 25.02% 27.23% 24.41% 27.30% 24.10% 24.15%
Operating Return on Assets (OROA)		 19.38% 15.55% 21.86% 20.40% 21.60% 22.87% 22.52% 22.89% 22.13% 23.61% 23.11%
Return on Assets (ROA)		 14.61% 11.91% 17.01% 16.43% 17.51% 18.86% 19.73% 19.27% 17.67% 19.04% 18.87%
Return on Common Equity (ROCE)		 23.72% 20.56% 26.84% 26.10% 26.08% 27.16% 28.32% 26.61% 24.24% 25.57% 25.53%
Return on Equity Simple (ROE_SIMPLE)		 21.33% 19.87% 20.70% 0.00% 21.42% 23.77% 23.68% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 233 221 300 311 314 344 373 377 348 389 397
NOPAT Margin		 21.13% 19.04% 25.05% 25.46% 25.68% 26.81% 28.84% 27.95% 26.08% 27.34% 27.72%
Net Nonoperating Expense Percent (NNEP)		 1.56% 0.98% -0.06% 2.28% 0.44% -0.15% 2.94% 8.06% 0.09% 1.18% 0.32%
Return On Investment Capital (ROIC_SIMPLE)		 - 3.88% - - - 5.80% 5.99% 5.68% 5.13% 5.57% 5.54%
Cost of Revenue to Revenue		 45.56% 44.36% 42.12% 41.50% 41.43% 41.40% 40.67% 39.16% 38.54% 38.24% 37.76%
SG&A Expenses to Revenue		 20.22% 19.11% 19.21% 19.80% 19.52% 18.85% 18.99% 19.67% 19.41% 19.57% 19.96%
R&D to Revenue		 6.87% 6.35% 6.44% 6.61% 6.49% 6.35% 6.50% 6.41% 6.54% 6.39% 6.59%
Operating Expenses to Revenue		 28.22% 31.98% 26.58% 27.33% 26.94% 26.05% 26.33% 27.12% 28.02% 27.20% 27.33%
Earnings before Interest and Taxes (EBIT)		 291 273 386 363 384 418 417 451 437 487 488
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 344 326 441 418 438 474 468 525 494 549 557
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.06 5.59 6.26 5.77 6.90 6.39 5.93 6.34 6.55 5.56 5.04
Price to Tangible Book Value (P/TBV)		 24.60 22.96 22.43 18.26 19.60 16.70 14.50 15.40 15.24 12.35 10.82
Price to Revenue (P/Rev)		 4.92 5.57 6.32 5.99 7.46 6.81 6.55 7.35 7.62 6.51 5.91
Price to Earnings (P/E)		 23.74 28.15 30.25 27.48 32.23 26.88 25.03 27.01 27.87 23.66 21.52
Dividend Yield		 1.23% 1.08% 0.95% 1.01% 0.81% 0.88% 0.92% 0.82% 0.80% 0.94% 1.04%
Earnings Yield		 4.21% 3.55% 3.31% 3.64% 3.10% 3.72% 3.99% 3.70% 3.59% 4.23% 4.65%
Enterprise Value to Invested Capital (EV/IC)		 4.20 4.74 5.51 5.35 6.63 6.24 6.17 6.87 7.28 6.18 5.77
Enterprise Value to Revenue (EV/Rev)		 5.18 5.79 6.49 6.09 7.51 6.84 6.50 7.25 7.49 6.37 5.73
Enterprise Value to EBITDA (EV/EBITDA)		 16.39 18.95 20.38 18.66 22.27 19.05 18.14 19.57 20.06 16.89 14.91
Enterprise Value to EBIT (EV/EBIT)		 19.28 22.45 23.93 21.73 25.70 21.74 20.62 22.33 22.86 19.21 17.02
Enterprise Value to NOPAT (EV/NOPAT)		 24.29 28.21 30.29 26.77 31.49 26.57 24.30 26.50 27.32 23.15 20.98
Enterprise Value to Operating Cash Flow (EV/OCF)		 24.25 24.17 24.83 20.36 25.07 22.84 19.73 21.29 20.90 17.97 16.78
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 36.64 34.04 26.52 32.73 24.73 22.42 28.39 26.58 26.02 24.35
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.32 0.27 0.22 0.15 0.13 0.13 0.12 0.11 0.11 0.11 0.10
Long-Term Debt to Equity		 0.32 0.27 0.22 0.14 0.13 0.13 0.12 0.11 0.07 0.06 0.06
Financial Leverage		 0.23 0.31 0.25 0.19 0.15 0.12 0.05 -0.01 -0.04 -0.05 -0.10
Leverage Ratio		 1.55 1.65 1.58 1.51 1.48 1.44 1.41 1.39 1.37 1.35 1.36
Compound Leverage Factor		 1.45 1.57 1.54 1.49 1.48 1.44 1.42 1.41 1.40 1.38 1.40
Debt to Total Capital		 24.26% 21.49% 17.86% 12.69% 11.54% 11.35% 10.82% 10.07% 9.85% 9.50% 9.28%
Short-Term Debt to Total Capital		 0.18% 0.17% 0.18% 0.18% 0.17% 0.17% 0.16% 0.15% 3.83% 3.72% 3.63%
Long-Term Debt to Total Capital		 24.08% 21.32% 17.69% 12.52% 11.37% 11.19% 10.66% 9.92% 6.02% 5.78% 5.65%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 75.74% 78.51% 82.14% 87.31% 88.46% 88.65% 89.18% 89.93% 90.15% 90.50% 90.72%
Debt to EBITDA		 0.98 0.89 0.69 0.46 0.42 0.38 0.37 0.35 0.34 0.33 0.31
Net Debt to EBITDA		 0.83 0.74 0.53 0.31 0.15 0.09 -0.14 -0.28 -0.36 -0.37 -0.47
Long-Term Debt to EBITDA		 0.98 0.88 0.68 0.46 0.41 0.37 0.37 0.35 0.21 0.20 0.19
Debt to NOPAT		 1.46 1.33 1.02 0.66 0.59 0.53 0.50 0.47 0.46 0.45 0.44
Net Debt to NOPAT		 1.23 1.10 0.78 0.44 0.22 0.12 -0.19 -0.38 -0.50 -0.51 -0.66
Long-Term Debt to NOPAT		 1.45 1.32 1.01 0.65 0.58 0.52 0.49 0.47 0.28 0.27 0.27
Altman Z-Score		 7.16 8.19 10.08 10.51 12.76 12.96 12.04 12.50 13.21 11.95 10.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.99 3.11 3.04 2.59 2.92 3.33 3.41 3.44 2.89 3.06 3.01
Quick Ratio		 1.17 1.23 1.32 1.18 1.37 1.62 1.96 2.11 1.82 1.93 1.97
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1,149 8.63 191 322 271 438 485 283 388 225 188
Operating Cash Flow to CapEx		 953.16% 1,168.30% 1,897.18% 1,768.88% 1,824.76% 1,494.98% 2,782.56% 1,761.54% 1,064.40% 1,190.46% 1,646.56%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 17.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 36.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 34.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.73 0.66 0.68 0.69 0.69 0.70 0.70 0.68 0.68 0.69 0.68
Accounts Receivable Turnover		 6.66 6.43 6.26 6.08 6.39 6.20 5.95 5.79 6.12 5.85 5.81
Inventory Turnover		 2.15 2.10 2.20 2.23 2.17 2.26 2.45 2.39 2.25 2.34 2.40
Fixed Asset Turnover		 8.57 8.38 8.58 8.63 8.79 9.19 9.34 9.37 9.36 9.96 10.05
Accounts Payable Turnover		 10.93 10.15 11.95 10.45 9.55 9.70 10.36 8.11 8.13 8.97 8.58
Days Sales Outstanding (DSO)		 54.77 56.81 58.34 60.07 57.08 58.89 61.31 63.01 59.65 62.40 62.83
Days Inventory Outstanding (DIO)		 169.74 173.49 165.73 163.64 168.26 161.61 149.10 152.71 162.06 155.89 152.24
Days Payable Outstanding (DPO)		 33.38 35.96 30.55 34.93 38.23 37.63 35.25 45.02 44.87 40.67 42.54
Cash Conversion Cycle (CCC)		 191.13 194.34 193.52 188.79 187.10 182.86 175.17 170.70 176.84 177.61 172.54
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5,403 5,498 5,399 5,333 5,446 5,404 5,286 5,427 5,406 5,568 5,495
Invested Capital Turnover		 0.93 0.84 0.86 0.88 0.89 0.90 0.94 0.96 0.97 0.98 1.03
Increase / (Decrease) in Invested Capital		 1,382 213 108 -10 43 -94 -113 94 -40 164 209
Enterprise Value (EV)		 22,676 26,085 29,763 28,523 36,120 33,722 32,616 37,289 39,363 34,406 31,705
Market Capitalization		 21,524 25,069 28,994 28,054 35,869 33,571 32,876 37,830 40,078 35,159 32,702
Book Value per Share		 $28.90 $30.47 $31.48 $33.11 $35.36 $35.78 $37.76 $40.70 $41.81 $43.30 $44.56
Tangible Book Value per Share		 $5.95 $7.42 $8.79 $10.46 $12.46 $13.69 $15.44 $16.75 $17.96 $19.50 $20.76
Total Capital		 5,612 5,709 5,637 5,571 5,873 5,926 6,219 6,636 6,790 6,985 7,156
Total Debt		 1,361 1,227 1,007 707 677 673 673 668 669 664 664
Total Long-Term Debt		 1,352 1,217 997 697 668 663 663 658 409 404 404
Net Debt		 1,152 1,016 769 469 251 151 -260 -541 -715 -753 -996
Capital Expenditures (CapEx)		 30 23 21 25 18 21 21 31 43 29 34
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,335 1,414 1,350 1,219 1,321 1,472 1,345 1,287 1,246 1,414 1,312
Debt-free Net Working Capital (DFNWC)		 1,544 1,624 1,588 1,457 1,747 1,994 2,278 2,496 2,630 2,831 2,973
Net Working Capital (NWC)		 1,534 1,614 1,578 1,447 1,737 1,984 2,268 2,486 2,370 2,571 2,713
Net Nonoperating Expense (NNE)		 14 13 -0.67 19 3.10 -0.89 7.49 -2.91 -0.20 -3.55 -1.99
Net Nonoperating Obligations (NNO)		 1,152 1,016 769 469 251 151 -260 -541 -715 -753 -996
Total Depreciation and Amortization (D&A)		 53 53 55 55 54 56 52 74 58 62 69
Debt-free, Cash-free Net Working Capital to Revenue		 30.50% 31.39% 29.45% 26.01% 27.47% 29.88% 26.79% 25.01% 23.71% 26.19% 23.70%
Debt-free Net Working Capital to Revenue		 35.28% 36.05% 34.64% 31.10% 36.34% 40.48% 45.36% 48.51% 50.03% 52.44% 53.68%
Net Working Capital to Revenue		 35.06% 35.83% 34.43% 30.89% 36.13% 40.27% 45.16% 48.32% 45.08% 47.62% 48.99%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.49 $1.42 $2.04 $1.99 $2.12 $2.35 $2.49 $2.59 $2.38 $2.69 $2.74
Adjusted Weighted Average Basic Shares Outstanding		 147.08M 147.13M 146.96M 147.02M 146.86M 146.81M 146.72M 146.72M 146.18M 145.84M 145.34M
Adjusted Diluted Earnings per Share		 $1.49 $1.42 $2.04 $1.97 $2.11 $2.34 $2.48 $2.58 $2.37 $2.68 $2.74
Adjusted Weighted Average Diluted Shares Outstanding		 147.49M 147.55M 147.45M 147.55M 147.60M 147.48M 147.22M 147.34M 146.90M 146.37M 145.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 147.09M 147.09M 146.91M 146.93M 146.80M 146.87M 146.63M 146.41M 145.97M 145.68M 145.06M
Normalized Net Operating Profit after Tax (NOPAT)		 233 273 300 311 314 344 373 377 361 394 397
Normalized NOPAT Margin		 21.13% 23.48% 25.05% 25.46% 25.68% 26.81% 28.84% 27.95% 27.00% 27.67% 27.72%
Pre Tax Income Margin		 24.69% 22.31% 31.36% 29.25% 31.32% 32.63% 32.34% 33.98% 33.45% 34.87% 35.09%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 35.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 27.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 33.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 25.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 29.57% 30.80% 29.09% 27.78% 26.10% 23.82% 23.20% 22.26% 22.31% 22.25% 22.39%
Augmented Payout Ratio		 29.57% 36.42% 39.53% 42.47% 44.07% 41.84% 42.24% 43.67% 50.13% 55.91% 61.87%

Financials Breakdown Chart

Key Financial Trends

ResMed’s latest quarterly results show a business that is still growing solidly, generating strong cash flow, and returning capital to shareholders, but with some signs of margin pressure and balance sheet leverage building over the last year.

For Q3 2026, revenue rose to $1.43 billion from $1.42 billion in Q2 2026 and $1.34 billion in Q1 2026. Net income improved to $398.7 million, up from $392.6 million in Q2 and $348.5 million in Q1. Earnings per share also ticked higher to $2.74 from $2.69 and $2.38, showing continued earnings momentum.

Cash generation remains a clear strength. Operating cash flow reached $554.1 million in Q3 2026, up from $339.7 million in Q2 and $457.3 million in Q1. Even after capital spending, acquisitions, dividends, and share repurchases, ResMed still produced positive net cash flow for the quarter.

The company also appears to be using excess cash aggressively. In Q3 2026, it repurchased $175.0 million of common stock and paid $87.2 million in dividends. That’s a shareholder-friendly capital return profile, especially given the company’s ongoing profitability.

  • Revenue continued to climb, with Q3 2026 sales of $1.43 billion versus $1.42 billion in Q2 2026 and $1.34 billion in Q1 2026.
  • Net income and EPS improved sequentially, indicating stable profitability and modest operating leverage.
  • Operating cash flow was very strong at $554.1 million in Q3 2026, comfortably covering dividends, buybacks, and capex.
  • Gross profit remained healthy, with Q3 gross profit of $891.0 million, reflecting a strong core business model.
  • Shareholder returns are meaningful, as the company continued buying back stock and paying a regular dividend.
  • Debt levels were relatively stable quarter to quarter, with short-term debt around $260 million and long-term debt near $404 million in Q3 2026.
  • Cash and equivalents increased sharply to $1.66 billion in Q3 2026 from $1.42 billion in Q2 2026, partly supported by operating cash flow.
  • Working capital remains substantial, helped by large inventories and receivables, which is typical for a medical device company but worth monitoring.
  • Operating expenses are rising in absolute dollars, especially SG&A and R&D, which could pressure margins if revenue growth slows.
  • Balance sheet leverage has increased over the past year, with long-term debt rising from $668 million in Q3 2025 to $404 million in Q3 2026, but still well above the low level seen in prior periods after accounting changes and acquisitions.

Looking at the longer trend, ResMed has expanded revenue materially over the last four years, from about $864.5 million in Q3 2022 to $1.43 billion in Q3 2026. Net income also rose from $179.0 million to $398.7 million over the same period. That suggests the company has been able to grow earnings alongside sales, which is a positive sign for long-term investors.

There are a few things to watch, though. The company has completed acquisitions over time, which helped grow goodwill to $3.04 billion in Q3 2026. That is not necessarily a problem, but it does mean a sizable portion of assets is intangible and acquisition-related. Also, the large share repurchase program and dividend payments continue to consume cash, so investors should monitor whether free cash flow stays strong enough to support both growth spending and capital returns.

Bottom line: ResMed looks fundamentally healthy, with solid growth, strong cash flow, and attractive capital returns. The main watch items are expense growth, debt, and the sustainability of margins if revenue growth cools.

06/11/26 06:13 PM ETAI Generated. May Contain Errors.

ResMed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ResMed's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

ResMed's net income appears to be on an upward trend, with a most recent value of $1.40 billion in 2025, rising from $352.89 million in 2015. The previous period was $1.02 billion in 2024. See ResMed's forecast for analyst expectations on what's next for the company.

ResMed's total operating income in 2025 was $1.69 billion, based on the following breakdown:
  • Total Gross Profit: $3.05 billion
  • Total Operating Expenses: $1.37 billion

Over the last 10 years, ResMed's total revenue changed from $1.68 billion in 2015 to $5.15 billion in 2025, a change of 206.5%.

ResMed's total liabilities were at $2.21 billion at the end of 2025, a 9.9% increase from 2024, and a 271.2% increase since 2015.

In the past 10 years, ResMed's cash and equivalents has ranged from $147.13 million in 2019 to $1.21 billion in 2025, and is currently $1.21 billion as of their latest financial filing in 2025.

Over the last 10 years, ResMed's book value per share changed from 11.26 in 2015 to 40.70 in 2025, a change of 261.3%.


Related Companies

Financial statements for NYSE:RMD last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel